article thumbnail

Venture capital funding in 2022 significantly decreased compared to 2021

Fox Corporate Finance

The ever-increasing venture capital funding for European life sciences companies halted in 2022. With a roughly EUR 9.6bn volume, the overall financing for European life sciences companies in 2022 decreased significantly compared to 2021 (EUR.

article thumbnail

US Biotech Venture Capital Funding in 2021 significantly exceeds Funding in 2020

Fox Corporate Finance

With a volume of roughly USD 33.0bn, the overall financing for US biotech companies in 2021 yet again surpassed the total funding of the previous year (USD 22.4bn). Compared to 2020, the funding volume increased.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Overall negative Life Sciences Sentiments recorded in August 2022

Fox Corporate Finance

The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector. For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech, Read more.

article thumbnail

Overall negative Life Sciences Sentiments recorded in August 2022

Fox Corporate Finance

The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector. For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech, Read more.

article thumbnail

Do Venture Capital Funds Overstate Their Performance? The Effects of FOIA

Reynolds Holding

It is based on a recent article, “ Bias in the Reporting of Venture Capital Performance: The Disciplinary Role of FOIA ,”which she co-wrote with Janet Kiholm Smith, a professor at Claremont McKenna College’s Robert Day School of Economics and Finance, and Richard L.

article thumbnail

European VC life sciences funding continues to decline

Fox Corporate Finance

In 2022, the venture capital funding for life sciences in Europe continues to weaken, further widening the gap to 2021 (EUR 9.4bn vs. EUR 6.5bn). The cumulative financing volume in August 2022 falls by more.

article thumbnail

US year-to-date funding volume now below previous year’s level

Fox Corporate Finance

After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined.